← Back to Search

Antiplatelet Agent

Rivaroxaban 2.5 Mg Oral Tablet bid for Ischemic Stroke

Phase 3
Waitlist Available
Led By Kanjana S. Perera, MD, FRCPC
Research Sponsored by Population Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from randomization to end of recruitment (2 years)
Awards & highlights

Study Summary

This trial will compare the effects of rivaroxaban + aspirin versus aspirin alone in preventing recurrent strokes in patients who have had a recent ischemic stroke.

Eligible Conditions
  • Ischemic Stroke
  • Stroke
  • Intracranial Atherosclerosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from randomization to end of recruitment (2 years)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from randomization to end of recruitment (2 years) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence rate of Intracranial hemorrhage
Recruitment rate
Refusal rate
+1 more
Secondary outcome measures
Combination of ISTH major hemorrhages & clinically-relevant non-major hemorrhages
Composite of stroke, myocardial infarction or vascular death
Major hemorrhage
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Experimental (riva + ASA)Experimental Treatment2 Interventions
Rivaroxaban 2.5mg bid + aspirin 81mg qd
Group II: Control (ASA alone)Active Control1 Intervention
Aspirin 81 mg qd
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rivaroxaban 2.5 Mg Oral Tablet bid
2020
Completed Phase 3
~110
Acetylsalicyclic acid 81 mg tablet qd
2020
Completed Phase 3
~110

Find a Location

Who is running the clinical trial?

Population Health Research InstituteLead Sponsor
155 Previous Clinical Trials
679,811 Total Patients Enrolled
4 Trials studying Ischemic Stroke
12,826 Patients Enrolled for Ischemic Stroke
Kanjana S. Perera, MD, FRCPCPrincipal InvestigatorHamilton Health Sciences Corporation

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA cleared Rivaroxaban 2.5 Mg Oral Tablet for use?

"There is both efficacy and safety data from previous clinical trials, meaning that Rivaroxaban 2.5 Mg Oral Tablet bid scored a 3 on our safety scale."

Answered by AI

What are Rivaroxaban 2.5 Mg Oral Tablets typically taken for?

"Rivaroxaban 2.5 Mg Oral Tablet bid is most commonly used for treatment of pain. It can also be used to treat multiple other conditions including myocardial infarction, catarrh, fractures, and bone."

Answered by AI

Are there other instances in which Rivaroxaban 2.5 Mg Oral Tablet has been tested in a clinical setting?

"Rivaroxaban 2.5 Mg Oral Tablet bid was first studied in the year 2002 at Institut Curie Hopital. To date there have been 706 completed trials. There are currently 230 active trials, with many of these trials running out of Calgary, Alberta."

Answered by AI

Is this a new clinical trial or have similar ones been conducted in the past?

"Rivaroxaban 2.5 Mg Oral Tablet bid has been trialed in 706 studies over the last 18 years. The first of these trials occurred in 2002 and the most recent one is ongoing. These studies have taken place across 64 countries and involved a total of 413 patients."

Answered by AI

What goals does this research aim to achieve?

"The key metric that will be used to judge the success of this clinical trial is the retention rate, which will be followed for 2 years. Other important outcomes include the recurrent ischemic stroke (in the area of the qualifying stenosis), major hemorrhage (as defined by ISTH criteria), and composite of stroke, myocardial infarction or vascular death."

Answered by AI

Is there room in this research project for more participants?

"The information available on clinicaltrials.gov suggests that this trial is not enrolling patients at the current moment. The trial was first posted on February 3rd, 2020 and was edited September 9th, 2020. Although this research is not looking for subjects as of now, there are 1,591 other trials that are."

Answered by AI

How many individuals are being given this experimental treatment?

"This study is no longer enrolling patients. It was originally posted on February 3rd, 2020 and was last updated on September 9th, 2020. However, there are 1361 other trials for wake-up stroke and 230 trials for Rivaroxaban 2.5 Mg Oral Tablet bid that are still looking for patients."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease
2020. "Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04142125.
~20 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top